DIVI'S LABORATORIES LTD. - 532488 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Annual Secretarial Compliance Report for the year ended March 31, 2023 issued by Mr. V. Bhaskara Rao, Practicing Company Secretary, Hyderabad.
Divis Lab Share Price Live blog for 23 May 2023
The opening price of Divis Lab was 3090 and it reached a high of 3271.15 during the session. However, it also went down to a low of 3050.15. DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclose herewith copies of newspapers publication regarding extracts of audited financial results of the Company for the quarter and year ended March 31, 2023. This notice is published on May 21, 2023 in Financial Express (English daily - All editions) and Andhra Prabha (Telugu daily - Hyderabad edition). FY23 Annual Result Announced for Divi's Laboratories Ltd.
Pharmaceuticals company Divi's Laboratories announced consolidated FY23 results: Total income of Rs 8,112 crore for FY23 as against Rs 9,074 crore during FY22 Total income is about 11 % lower than FY22 because of a significantly lower volume of covid situational opportunity PBT for FY23 came to Rs 2,369 crore as against Rs 3,684 crore for FY22 PAT for FY23 amounted to Rs 1,823 crore as against a PAT of Rs 2,960 crore The board of directors of the company has proposed a dividend of Rs 30 per share of face value Rs 2 each i.e., 1500% for FY23, subject to approval of members. Result PDF Divis Lab Share Price Live blog for 22 May 2023
Divis Lab opened at 3146.3 and reached a high of 3156.05 in the current session. However, it also saw a low of 3085.2. DIVI'S LABORATORIES LTD. - 532488 - Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2023
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose disclosure of Related Party Transactions in the specified format for the half year ended March 31, 2023.
Divi's Laboratories Results Earnings Call for Q4FY23
Conference Call with Divi's Laboratories Ltd. Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Murali Divi and Senior Team DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of earnings conference call Q4 and full year FY23 held on May 20, 2023. DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Audited Financial Results of the Company for the quarter and year ended March 31, 2023